bluebird bio, Inc. Expected to Post FY2023 Earnings of ($1.86) Per Share (NASDAQ:BLUE)

bluebird bio, Inc. (NASDAQ:BLUEFree Report) – Research analysts at Wedbush dropped their FY2023 earnings estimates for shares of bluebird bio in a research report issued on Monday, March 18th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($1.86) per share for the year, down from their previous estimate of ($1.80). Wedbush has a “Neutral” rating and a $1.68 price objective on the stock. The consensus estimate for bluebird bio’s current full-year earnings is ($1.77) per share. Wedbush also issued estimates for bluebird bio’s Q4 2023 earnings at ($0.74) EPS, Q1 2024 earnings at ($0.62) EPS, Q2 2024 earnings at ($0.55) EPS, Q3 2024 earnings at ($0.51) EPS, Q4 2024 earnings at ($0.47) EPS, FY2024 earnings at ($2.15) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.43) EPS and FY2027 earnings at ($0.25) EPS.

A number of other brokerages also recently commented on BLUE. HSBC lowered their price target on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a report on Tuesday, March 5th. Robert W. Baird lowered their target price on shares of bluebird bio from $10.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, December 12th. Bank of America reduced their price objective on shares of bluebird bio from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 21st. upgraded bluebird bio to a “sell” rating in a research report on Friday, December 8th. Finally, Morgan Stanley upgraded bluebird bio from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $3.00 to $7.00 in a report on Friday, December 8th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, bluebird bio currently has an average rating of “Hold” and an average price target of $6.27.

Read Our Latest Research Report on BLUE

bluebird bio Stock Up 4.3 %

BLUE stock opened at $1.46 on Thursday. bluebird bio has a 52 week low of $0.88 and a 52 week high of $5.53. The firm has a market capitalization of $159.63 million, a P/E ratio of -1.97 and a beta of 0.75. The company has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $2.36.

Hedge Funds Weigh In On bluebird bio

Several institutional investors and hedge funds have recently bought and sold shares of BLUE. US Bancorp DE lifted its stake in bluebird bio by 885.7% during the second quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 6,749 shares in the last quarter. Raymond James & Associates acquired a new stake in shares of bluebird bio during the first quarter worth about $50,000. Stifel Financial Corp acquired a new position in shares of bluebird bio in the third quarter valued at approximately $32,000. Penserra Capital Management LLC purchased a new stake in bluebird bio during the 1st quarter worth approximately $53,000. Finally, Aigen Investment Management LP purchased a new position in bluebird bio in the 3rd quarter valued at approximately $34,000. 87.43% of the stock is currently owned by institutional investors and hedge funds.

About bluebird bio

(Get Free Report)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Featured Articles

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with's FREE daily email newsletter.